Immunoinformatic approach to design an efficient multi‐epitope peptide vaccine against melanoma
Biotechnology and Applied Biochemistry · 2025
DOI: 10.1002/bab.2654 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biotechnology and Applied Biochemistry, 2025. Verfasst von Mahvash Dehghankhold und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Nanotechnology, Shiraz University of Medical Sciences, Shiraz, Iran. Hauptthemen laut MEDLINE: Cancer Vaccines, Melanoma, Vaccines, Subunit, Epitopes. Die Arbeit nennt 93 Literaturangaben.
Abstract (Originalsprache)
Melanoma is known to be the most hazardous and life‐threatening type of skin cancer. Although numerous treatments have been authorized in recent years, they often result in severe side effects and may not fully cure the disease. To combat this issue, immunotherapy has emerged as a promising approach for the prevention and treatment of melanoma. Specifically, the use of epitope melanoma vaccine, a subset of immunotherapy, has recently gained attention. The aim of this study was to create a multi‐epitope melanoma vaccine using immunoinformatic methods. Two well‐known antigens, NYESO‐1 and MAGE‐C2, were selected due to their strong immunogenicity and high expression in melanoma. To enhance the immunogenicity of the peptide vaccine, Brucella cell‐surface protein 31 (BCSP31), the G5 domain of resuscitation‐promoting factor B (RpfB) adjuvants, and the helper epitope of pan HLADR‐binding epitope (PADRE) were incorporated to vaccine construct. These different segments were connected with suitable linkers and the resulting vaccine structure was evaluated for its physicochemical, structural, and immunological properties using computational tools. The designed vaccine was found to have satisfactory allergenicity, antigenicity, and physicochemical parameters. Additionally, a high‐quality tertiary structure of the vaccine was achieved through modeling, refinement, and validation. Docking and molecular dynamics studies showed that the vaccine had a stable and appropriate interaction with the cognate TLR2 and TLR4 receptors during the simulation period. Finally, in silico immune simulation analysis revealed a significant increase in the levels of helper and cytotoxic T cells, as well as the cytokines interferon‐gamma and interleukin‐2, after repeated exposure to the melanoma vaccine. These results suggest that the designed vaccine has the potential to be an effective therapeutic option for melanoma. However, additional in vitro and in vivo validations are crucial to assess real‐world efficacy and safety.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Nanotechnology, Shiraz University of Medical Sciences, Shiraz, Iran.
- Pharmaceutical Sciences Research Center, Shiraz University of Medical Science, Shiraz, Iran.
- Department of Pharmaceutical Biotechnology, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
- Computational Vaccine and Drug Design Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
- Department of Pharmaceutical Nanotechnology and Center for Nanotechnology in Drug Delivery, Shiraz University of Medical Sciences, Shiraz, Iran.
ORCID-Profile: Navid Nezafat
Zitieren
APA
Dehghankhold, M., Nezafat, N., Farahmandnejad, M., Abolmaali, S. S., & Tamaddon, A. M. (2025). Immunoinformatic approach to design an efficient multi‐epitope peptide vaccine against melanoma. Biotechnology and Applied Biochemistry. https://doi.org/10.1002/bab.2654
Vancouver
Dehghankhold M, Nezafat N, Farahmandnejad M, Abolmaali SS, Tamaddon AM. Immunoinformatic approach to design an efficient multi‐epitope peptide vaccine against melanoma. Biotechnology and Applied Biochemistry. 2025. doi:10.1002/bab.2654
BibTeX
@article{Dehghankhold2025,
author = {Dehghankhold, Mahvash and Nezafat, Navid and Farahmandnejad, Mitra and Abolmaali, Samira Sadat and Tamaddon, Ali Mohammad},
title = {Immunoinformatic approach to design an efficient multi‐epitope peptide vaccine against melanoma},
journal = {Biotechnology and Applied Biochemistry},
year = {2025},
doi = {10.1002/bab.2654}
}
EUVIMED